CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.468
NA - Nord America 1.928
EU - Europa 1.912
SA - Sud America 414
AF - Africa 92
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 7.817
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.844
IT - Italia 1.269
SG - Singapore 1.114
CN - Cina 1.092
HK - Hong Kong 567
BR - Brasile 339
KR - Corea 286
IN - India 127
DE - Germania 111
GB - Regno Unito 102
SE - Svezia 101
CH - Svizzera 73
VN - Vietnam 70
RU - Federazione Russa 64
FI - Finlandia 35
CA - Canada 31
BD - Bangladesh 29
JP - Giappone 27
PL - Polonia 27
MX - Messico 26
AR - Argentina 25
CI - Costa d'Avorio 25
FR - Francia 25
ZA - Sudafrica 25
TR - Turchia 24
AT - Austria 23
IQ - Iraq 21
SA - Arabia Saudita 16
NL - Olanda 15
BG - Bulgaria 14
UA - Ucraina 13
CZ - Repubblica Ceca 11
PK - Pakistan 11
UZ - Uzbekistan 11
KE - Kenya 10
CL - Cile 9
JO - Giordania 9
VE - Venezuela 9
CO - Colombia 8
EC - Ecuador 7
IE - Irlanda 7
MA - Marocco 7
NP - Nepal 7
BB - Barbados 6
EG - Egitto 6
ES - Italia 6
TW - Taiwan 6
GT - Guatemala 5
PS - Palestinian Territory 5
PY - Paraguay 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
ID - Indonesia 4
JM - Giamaica 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
DO - Repubblica Dominicana 3
IL - Israele 3
IR - Iran 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
PH - Filippine 3
SN - Senegal 3
TN - Tunisia 3
AM - Armenia 2
BH - Bahrain 2
CG - Congo 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
NG - Nigeria 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
AL - Albania 1
AO - Angola 1
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CR - Costa Rica 1
EE - Estonia 1
EU - Europa 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
KW - Kuwait 1
LU - Lussemburgo 1
MD - Moldavia 1
Totale 7.810
Salva come PNG Salva come JPEG
Città #
Milan 781
Singapore 637
Hong Kong 559
Hefei 475
Santa Clara 422
Ashburn 289
Seoul 286
Shanghai 245
Boardman 161
Dallas 154
New York 122
Pisa 114
Los Angeles 87
Rome 83
Bern 72
Beijing 70
Hyderabad 62
Fairfield 58
London 50
Seattle 42
Frankfurt am Main 39
Florence 38
Munich 35
Redondo Beach 31
Woodbridge 31
Buffalo 30
Chicago 28
São Paulo 28
Warsaw 26
Abidjan 25
Tokyo 24
Ho Chi Minh City 23
Houston 20
Wilmington 18
Helsinki 17
Nuremberg 17
Serra 16
Cambridge 15
Chandler 15
Ann Arbor 14
Sofia 13
Rio de Janeiro 11
Tashkent 11
Turku 11
Elk Grove Village 10
Fuzhou 10
Hanoi 10
Istanbul 10
Johannesburg 10
Amman 9
Dhaka 9
Falkenstein 9
Mexico City 9
Belo Horizonte 8
Brno 8
Chennai 8
Lucknow 8
Nairobi 8
Pune 8
Vienna 8
Dublin 7
Ottawa 7
San Francisco 7
San Jose 7
Bridgetown 6
Cape Town 6
Montreal 6
Mumbai 6
Porto Alegre 6
Riyadh 6
Baghdad 5
Cairo 5
Erbil 5
Guatemala City 5
Lawrence 5
Medford 5
Princeton 5
Salt Lake City 5
Shenzhen 5
Buenos Aires 4
Chiswick 4
Council Bluffs 4
Dammam 4
Des Moines 4
Durban 4
Haiphong 4
Jeddah 4
Kathmandu 4
Montevideo 4
New Delhi 4
Nocera Superiore 4
Nova Iguaçu 4
Orem 4
Poplar 4
Recife 4
Roubaix 4
Salvador 4
Santiago 4
Taichung 4
Tampa 4
Totale 5.640
Salva come PNG Salva come JPEG
Nome #
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 169
IgG cryoglobulinemia 137
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 134
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 122
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 121
Thyroid Autoimmunity and SARS-CoV-2 Infection 121
HCV-related rheumatic manifestations and therapeutic strategies 121
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 120
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 118
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 118
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 117
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 116
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 116
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 114
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 114
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 113
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 113
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 113
Host genetic determinants in HCV-related mixed cryoglobulinemia 112
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 112
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 112
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 111
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 111
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 110
Treatment of HCV-related mixed cryoglobulinemia 110
HCV and lymphoproliferation 109
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 107
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 105
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 105
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 104
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 104
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 104
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 103
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 103
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 102
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 102
HCV infection, malignancy and liver transplantation 102
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 101
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 101
The Hepatitis C Virus Infection as a Systemic Disease 99
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 99
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 98
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 98
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 97
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 97
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 97
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 96
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 95
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 95
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 93
HCV AND lymphoma: Genetic and epigenetic factors 83
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 81
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 75
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 73
HBV and HCV testing outcomes among marginalized communities in Italy, 2019–2024: a prospective study 72
Role of notch receptors in hematologic malignancies 71
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 70
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 66
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 66
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 64
Host genetic determinants in HCV-related mixed cryoglobulinemia 61
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 60
Serological and Molecular Characterization of Hepatitis C Virus-Related Cryoglobulinemic Vasculitis in Patients without Cryoprecipitate 55
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 53
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 52
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 51
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 49
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 49
Hepatitis C virus lymphotrophism: lessons from a decade of studies 48
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 44
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 44
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 43
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 42
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 41
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 40
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 40
Free light chains: Eclectic multipurpose biomarker 40
Fibrosis assessment in patients with HCV or HBV chronic infection 39
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 38
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 37
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 36
Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals 36
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 34
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 34
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 34
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 33
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 32
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 31
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 30
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 30
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 30
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 29
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 28
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 27
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 26
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 26
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases 24
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 23
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma 23
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 23
Totale 7.727
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 0 0 5 1 6 5 5
2021/202275 0 1 5 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/20253.658 126 134 40 122 323 238 249 120 304 322 548 1.132
2025/20262.084 248 608 304 306 410 208 0 0 0 0 0 0
Totale 8.116